Definium Therapeutics, Inc. cotiza a 34.38 USD y tiene una capitalización bursátil de $4.6B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $-1.44 | $-0.71 | $-0.50 |
| Estimado | $-0.56 | $-0.55 | $-0.49 | $-0.49 |
| Sorpresa | — | -161.8% | -44.9% | -2.0% |
| Métrica | DFTX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -55.3% | -40.4% | -14.9% |
| ROA | -41.8% | -32.0% | -9.8% |
| Current Ratio | 6.29 | 2.84 | +3.45 |
| Debt / Equity | 0.12 | 0.28 | -0.16 |